Literature DB >> 9000606

Changes in nutritional status associated with unresectable pancreatic cancer.

S J Wigmore1, C E Plester, R A Richardson, K C Fearon.   

Abstract

Weight loss is common in patients with pancreatic cancer; however, the nature and progress of their nutritional depletion are not well documented. In this study, pre-illness weight and duration of weight loss were recorded in 20 patients with histologically confirmed unresectable cancer of the pancreas. Patients then underwent nutritional analysis at monthly intervals until death. The median period of assessment was 27 weeks (interquartile range 22.5-38.0 weeks). At the time of diagnosis, all patients had lost weight [median 14.2% (10.0-20.0%) of pre-illness stable weight], and this weight loss was progressive, increasing to a median of 24.5% by the time of the last assessment (P =0.0004). Body mass index was significantly reduced from a pre-illness median value of 24.9 kg m-2 (22.4-27.4 kg m-2) to 20.7 kg m-2 (19.5-23.6 kg m-2) at the time of diagnosis and further to 17.7 kg m-2 (16.6-23.1 kg m-2) just before death (P =0.0003). Further evidence of tissue depletion was evident from the significant reductions in lean body mass [43.4 kg (36.9-53.0 kg) to 40.1 kg (33.5-50.7 kg) P =0.008] and fat mass [12.5 kg (8.9-17.8 kg) to 9.6 kg (6.3-15.1 kg) P =0.03). This study confirms that the majority of patients with unresectable pancreatic cancer have already undergone significant weight loss by the time of diagnosis and that the natural history of this process is one of inexorable progression. These results highlight the need for selective non-toxic therapeutic intervention to attenuate cachexia and indicate that such interventions should be instituted early in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000606      PMCID: PMC2222706          DOI: 10.1038/bjc.1997.17

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Nutritional support in the adult cancer patient.

Authors:  F Bozzetti
Journal:  Clin Nutr       Date:  1992-08       Impact factor: 7.324

2.  Body composition analysis: an evaluation of 2 component models, multicomponent models and bedside techniques.

Authors:  M Elia
Journal:  Clin Nutr       Date:  1992-06       Impact factor: 7.324

3.  Artificial nutrition support in hospitals in the United Kingdom - 1991: Second national survey.

Authors:  J J Payne-James; C J De Gara; G K Grimble; M J Bray; S K Rana; S Kapadia; D B Silk
Journal:  Clin Nutr       Date:  1992-08       Impact factor: 7.324

4.  Impaired wound healing in surgical patients with varying degrees of malnutrition.

Authors:  D A Haydock; G L Hill
Journal:  JPEN J Parenter Enteral Nutr       Date:  1986 Nov-Dec       Impact factor: 4.016

5.  Pattern of sodium excretion accompanying starvation.

Authors:  P R Boulter; R S Hoffman; R A Arky
Journal:  Metabolism       Date:  1973-05       Impact factor: 8.694

Review 6.  Muscle function and nutrition.

Authors:  K N Jeejeebhoy
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

7.  Weight loss with physiologic impairment. A basic indicator of surgical risk.

Authors:  J A Windsor; G L Hill
Journal:  Ann Surg       Date:  1988-03       Impact factor: 12.969

8.  Energy and the maintenance of the body cell mass.

Authors:  F D Moore
Journal:  JPEN J Parenter Enteral Nutr       Date:  1980 May-Jun       Impact factor: 4.016

9.  Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

Authors:  J S Falconer; K C Fearon; C E Plester; J A Ross; D C Carter
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

10.  Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients.

Authors:  S J Wigmore; J S Falconer; C E Plester; J A Ross; J P Maingay; D C Carter; K C Fearon
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  64 in total

Review 1.  [Best supportive care of pancreatic carcinoma].

Authors:  K Schoppmeyer; J Mössner
Journal:  Internist (Berl)       Date:  2004-07       Impact factor: 0.743

2.  Cachexia in pancreatic cancer: new treatment options and measures of success.

Authors:  Kenneth C H Fearon; Vickie E Baracos
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 3.  The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature.

Authors:  Savita Joglekar; Peter N Nau; James J Mezhir
Journal:  J Surg Oncol       Date:  2015-08-27       Impact factor: 3.454

Review 4.  Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models.

Authors:  Sally E Henderson; Neil Makhijani; Thomas A Mace
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

5.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

6.  Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.

Authors:  K C H Fearon; M F Von Meyenfeldt; A G W Moses; R Van Geenen; A Roy; D J Gouma; A Giacosa; A Van Gossum; J Bauer; M D Barber; N K Aaronson; A C Voss; M J Tisdale
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival.

Authors:  Amro Mohamed Sedky El-Ghammaz; Rima Ben Matoug; Maha Elzimaity; Nevine Mostafa
Journal:  Support Care Cancer       Date:  2017-04-24       Impact factor: 3.603

8.  Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.

Authors:  Aminah Jatoi; Steven R Alberts; Nathan Foster; Roscoe Morton; Patrick Burch; Margaret Block; Phuong L Nguyen; John Kugler
Journal:  Support Care Cancer       Date:  2005-03-10       Impact factor: 3.603

9.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.

Authors:  J N Gordon; T M Trebble; R D Ellis; H D Duncan; T Johns; P M Goggin
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

10.  Functioning and health in patients with cancer on home-parenteral nutrition: a qualitative study.

Authors:  Martin Mueller; Stefanie Lohmann; Paul Thul; Arved Weimann; Eva Grill
Journal:  Health Qual Life Outcomes       Date:  2010-04-16       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.